Core Insights - Amplia Therapeutics Limited is making significant progress in the clinical development of its FAK inhibitor, narmafotinib, particularly for metastatic pancreatic cancer, with promising results from ongoing trials [2][3][17] Clinical Trial Updates - The ACCENT trial, which combines narmafotinib with gemcitabine and Abraxane®, has reported an overall response rate of 35%, significantly higher than the 23% response rate for chemotherapy alone [3][17] - The mean duration on trial for patients was 219 days, with some patients remaining on the study for over 12 months, indicating the drug's potential to halt cancer progression [4] - The AMPLICITY trial has commenced, investigating narmafotinib in combination with FOLFIRINOX chemotherapy, with patient recruitment ongoing in Melbourne and Sydney [6][7] Regulatory and Commercial Developments - Positive feedback from the US FDA has been received regarding the dose optimization strategy for narmafotinib, which supports its planned Phase 2b/3 trial [8] - A key patent for narmafotinib has been granted, extending protection until at least 2040 in the US and other jurisdictions [9] - Amplia has successfully uplisted to the US-based OTCQB Venture Market, enhancing its visibility and investor reach [10] Preclinical Studies - The second phase of a research collaboration with Next & Bio has been initiated, focusing on evaluating narmafotinib against patient-derived pancreatic cancer cells with specific genetic mutations [11] Financial Update - Amplia reported a cash position of $31.5 million at the end of December 2025, with net operating cash inflows of $2.4 million during the quarter [13] - The company received $3.8 million from government grants and tax incentives, while outflows included $0.9 million for staff and administration costs, and $0.9 million for research and development [14]

Core Insights - Amplia Therapeutics has successfully completed the first large-scale manufacture of narmafotinib, producing approximately 13 kg of the drug, marking a significant step towards Phase 3 readiness [1] - The transition from R&D to commercial manufacturing has been achieved, ensuring sufficient drug supply for ongoing pancreatic cancer trials and other planned studies [1][3] Manufacturing and Production - The company collaborated closely with its contract development and manufacturing organization (CDMO) to ensure a seamless transition to large-scale production, resulting in production efficiencies and significant cost savings [2] - The next step involves converting the 13 kg of active pharmaceutical ingredient (API) into oral capsules for clinical trials [2] Clinical Development - The newly manufactured API will support Amplia's pancreatic cancer trials and other studies currently in planning stages [3] - Dr. Rhiannon Jones emphasized the importance of this large-scale API synthesis campaign in preparing for the next stages of clinical development [4] Quality Standards - Narmafotinib is manufactured under Good Manufacturing Practice (GMP), ensuring that the product meets strict safety and quality requirements [4] Drug Information - Narmafotinib (AMP945) is a best-in-class inhibitor of the protein FAK, which is over-expressed in pancreatic cancer and is a significant target in solid tumors [6] - The drug has shown promising results in preclinical studies and is currently undergoing clinical trials, including the ACCENT trial, which has achieved a confirmed response rate of 35% [7]

Core Insights - Amplia Therapeutics Limited has entered the second phase of a research collaboration with Next & Bio to further investigate the efficacy of its FAK inhibitors in treating pancreatic cancer [2][3][4] - The collaboration aims to explore the synergistic effects of Amplia's FAK inhibitor narmafotinib in combination with kRAS inhibitors, which target genetic mutations present in over 90% of pancreatic cancers [3][4][9] - Initial studies have shown that narmafotinib demonstrated promising activity against patient-derived pancreatic cancer cells, with plans to present this data at an upcoming scientific conference [3][6] Company Overview - Amplia Therapeutics is an Australian pharmaceutical company focused on developing a pipeline of FAK inhibitors for cancer and fibrosis, particularly in fibrotic cancers like pancreatic and ovarian cancer [7] - Narmafotinib (AMP945) is Amplia's leading FAK inhibitor, which has shown significant potential in preclinical studies and is currently undergoing clinical trials in combination with established chemotherapies [8][10] Collaboration Details - The partnership with Next & Bio, a preclinical drug screening company, leverages patient-derived cell models to provide more accurate and predictive results for pancreatic cancer treatment [5][6] - The collaboration is expected to enhance Amplia's strategic positioning for future partnerships and commercial growth opportunities [6]